CASI Pharmaceuticals(CASIF)
BEIJING, ChinaPharmaceutical
Focus: CASI Pharmaceuticals is a 5000+ employee public company headquartered in Beijing focused on small molecule oncology and neurology therapeutics. The company operates as a mid-cap biotech with a geographically distributed pipeline across multiple cancer indications.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
5000+
Open Jobs
0
About CASI Pharmaceuticals
AI assessmentNot HiringNo open roles listed right now. Follow CASI Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
24 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Melphalan Hydrochloride for Injection
Stable
Post-LOE
Only Phase 4 program in pipeline; likely a marketed product or legacy asset with minimal growth upside.
Pipeline & Clinical Trials
Help build intelligence for CASI Pharmaceuticals
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.